Upgraded Relay Therapeutics to a buy after valuation decline. Read more on RLAY's pipeline progress, financial health, and ...

A cohort study of people who underwent fecal immunochemical (FIT) screening for colorectal cancer showed that interval cancer ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

Major stock indexes edged higher Monday to kick off what will be an extraordinarily busy week of news for financial markets.

Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of its underwritten public ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, B.C., July 29, 2025 /PRNewswire/ -- Equity Insider News Commentary - The average age of cancer patients is getting younger, ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, B.C., July 29, 2025 /PRNewswire/ -- Equity Insider News Commentary – ...

July brought major breast cancer updates, and CURE is sharing the latest, as recent developments underscore how quickly the landscape continues to evolve.

After Celcuity (CELC) announced topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial evaluating gedatolisib plus fulvestrant with and without palbociclib versus fulvestrant ...

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...

Celcuity ( (CELC)) has shared an announcement. On July 28, 2025, Celcuity Inc. announced positive topline results from its Phase 3 VIKTORIA-1 clinical trial, which evaluated gedatolisib plus ...